CAS-ViewAlert

View Alert




Originator:		CMO Messaging
From:		CMO Messaging
Issue date:		31-Dec-2020 19:23:26
This alert has been issued to:
		NHS Foundation Trusts (England) - Medical Director NHS Foundation Trusts (England) - Chief Executive NHS Trusts (England) - Medical Director NHS Trusts (England) - Chief Executive
		MHRA (Medicines) Drug Alerts (Various Recipients) Other contacts Independent Healthcare Providers (registered with CAS) Clinical Commissioning Groups Special Health Authorities CMO Urgent Messages - Non-NHS Recipients on Public Health Link MHRA (Medicines) Drug Alerts - Non-NHS Recipients Territorial CMOs in Northern Ireland, Scotland & Wales Regional Directors of Public Health Consultants in Communicable Diseases CMO Urgent Messages - Recipients on Public Health Link Director of Public Health GP - Locum NHS 111 and Out of hours providers GP Practices Out of hours contacts Community Pharmacy Primary Care Networks GP Practices 1
Action category:		Action
Title:		Letter from the UK Chief Medical Officers regarding the UK COVID-19 vaccination programmes
Broadcast content:		The attached letter sets out the scientific and public health rationale for the dosing schedule for the AstraZeneca vaccine and the change to the dosing schedule for the second dose of the Pfizer vaccine. The Joint Committee on Vaccination and Immunisation (JCVI) has put forward a prioritisation scheme, as included in the Green Book Chapter 14a (tables 2 and 3) which is attached. The JCVI have also issued a short statement 'Optimising the COVID-19 vaccination programme for maximum short-term impact' which is also attached.
Alert reference:		CEM/CMO/2020/044
Attachments:		CEM_CMO_2020_044.pdf CEM_CMO_2020_044_JCVI_Statement.pdf CEM_CMO_2020_044_GreenBook.pdf